193 related articles for article (PubMed ID: 34992456)
1. The Circadian Gene NPAS2 Act as a Putative Tumor Stimulative Factor for Uterine Corpus Endometrial Carcinoma.
Zheng X; Lv X; Zhu L; Xu K; Shi C; Cui L; Ding H
Cancer Manag Res; 2021; 13():9329-9343. PubMed ID: 34992456
[TBL] [Abstract][Full Text] [Related]
2. RNF183 Is a Prognostic Biomarker and Correlates With Tumor Purity, Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Geng R; Zheng Y; Zhao L; Huang X; Qiang R; Zhang R; Guo X; Li R
Front Genet; 2020; 11():595733. PubMed ID: 33324448
[TBL] [Abstract][Full Text] [Related]
3. miR-149-3p Is a Potential Prognosis Biomarker and Correlated with Immune Infiltrates in Uterine Corpus Endometrial Carcinoma.
Lu X; Jing L; Liu S; Wang H; Chen B
Int J Endocrinol; 2022; 2022():5006123. PubMed ID: 35719192
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of PSAT1 inhibits cell proliferation and migration in uterine corpus endometrial carcinoma.
Wang M; Yue S; Yang Z
Sci Rep; 2023 Mar; 13(1):4081. PubMed ID: 36906716
[TBL] [Abstract][Full Text] [Related]
5. A correlation study of adhesion G protein-coupled receptors as potential therapeutic targets in Uterine Corpus Endometrial cancer.
Lei P; Wang H; Yu L; Xu C; Sun H; Lyu Y; Li L; Zhang DL
Int Immunopharmacol; 2022 Jul; 108():108743. PubMed ID: 35413679
[TBL] [Abstract][Full Text] [Related]
6. MiR-29a-5p inhibits proliferation and invasion and induces apoptosis in endometrial carcinoma via targeting TPX2.
Jiang T; Sui D; You D; Yao S; Zhang L; Wang Y; Zhao J; Zhang Y
Cell Cycle; 2018; 17(10):1268-1278. PubMed ID: 29888640
[TBL] [Abstract][Full Text] [Related]
7. KDM4B, a potential prognostic biomarker revealed by large-scale public databases and clinical samples in uterine corpus endometrial carcinoma.
Zhang M; Liu Y; Hou S; Wang Y; Wang C; Yin Y; Chen X
Mol Omics; 2022 Jul; 18(6):506-519. PubMed ID: 35485290
[TBL] [Abstract][Full Text] [Related]
8. Identification of Hub Genes Correlated With Poor Prognosis for Patients With Uterine Corpus Endometrial Carcinoma by Integrated Bioinformatics Analysis and Experimental Validation.
Yuan Y; Chen Z; Cai X; He S; Li D; Zhao W
Front Oncol; 2021; 11():766947. PubMed ID: 34868993
[TBL] [Abstract][Full Text] [Related]
9. CD45RO
Zhou WJ; Zhang J; Xie F; Wu JN; Ye JF; Wang J; Wu K; Li MQ
Theranostics; 2021; 11(11):5330-5345. PubMed ID: 33859750
[No Abstract] [Full Text] [Related]
10. Identification and Validation of Cuproptosis-Related Prognostic Signature and Associated Regulatory Axis in Uterine Corpus Endometrial Carcinoma.
Chen Y
Front Genet; 2022; 13():912037. PubMed ID: 35937995
[No Abstract] [Full Text] [Related]
11. Long non‑coding RNA BLACAT2/miR‑378a‑3p/YY1 feedback loop promotes the proliferation, migration and invasion of uterine corpus endometrial carcinoma.
Zhang C; Wang R; Li M; Yang Q
Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052291
[TBL] [Abstract][Full Text] [Related]
12. TIMM8A is associated with dysfunction of immune cell in BRCA and UCEC for predicting anti-PD-L1 therapy efficacy.
Zhu X; Yuan Z; Cheng S; Wang H; Liao Y; Zhou D; Wu Z
World J Surg Oncol; 2022 Oct; 20(1):336. PubMed ID: 36207751
[TBL] [Abstract][Full Text] [Related]
13. KNL1 is a prognostic and diagnostic biomarker related to immune infiltration in patients with uterine corpus endometrial carcinoma.
He K; Li J; Huang X; Zhao W; Wang K; Wang T; Chen J; Wang Z; Yi J; Zhao S; Zhao L
Front Oncol; 2023; 13():1090779. PubMed ID: 36776306
[TBL] [Abstract][Full Text] [Related]
14. Myelin and Lymphocyte Protein (MAL): A Novel Biomarker for Uterine Corpus Endometrial Carcinoma.
Li D; Zhang J; Wu L; Yang X; Chen Z; Yuan J
Cancer Manag Res; 2021; 13():7311-7323. PubMed ID: 34584457
[TBL] [Abstract][Full Text] [Related]
15. FAT2 mutation is associated with better prognosis and responsiveness to immunotherapy in uterine corpus endometrial carcinoma.
Wang Z; Xing L; Huang Y; Han P
Cancer Med; 2023 Feb; 12(3):3797-3811. PubMed ID: 36812126
[TBL] [Abstract][Full Text] [Related]
16. The Expression of Pyroptosis-Related Gene May Influence the Occurrence, Development, and Prognosis of Uterine Corpus Endometrial Carcinoma.
Huang X; Li Y; Li J; Yang X; Xiao J; Xu F
Front Oncol; 2022; 12():885114. PubMed ID: 35574367
[TBL] [Abstract][Full Text] [Related]
17. ACE2 correlated with immune infiltration serves as a prognostic biomarker in endometrial carcinoma and renal papillary cell carcinoma: implication for COVID-19.
Yang J; Li H; Hu S; Zhou Y
Aging (Albany NY); 2020 Apr; 12(8):6518-6535. PubMed ID: 32339157
[TBL] [Abstract][Full Text] [Related]
18. Development and Clinical Validation of Novel 8-Gene Prognostic Signature Associated With the Proportion of Regulatory T Cells by Weighted Gene Co-Expression Network Analysis in Uterine Corpus Endometrial Carcinoma.
Liu J; Geng R; Yang S; Shao F; Zhong Z; Yang M; Ni S; Cai L; Bai J
Front Immunol; 2021; 12():788431. PubMed ID: 34970268
[TBL] [Abstract][Full Text] [Related]
19. RPP40 is a prognostic biomarker and correlated with tumor microenvironment in uterine corpus endometrial carcinoma.
Tang J; Tian X; Min J; Hu M; Hong L
Front Oncol; 2022; 12():957472. PubMed ID: 36091104
[TBL] [Abstract][Full Text] [Related]
20. LAMP3 is a potent uterine corpus endometrial carcinoma prognostic biomarker associated with immune behavior.
Fu B; Zhou M; Geng X; Jiang Y; Zeng H; Zhou X; Yu Z; Pan J; Zhu Y; Zheng H; Huang S; Gong Y; Huang D; Zhong Y
Aging (Albany NY); 2024 Jan; 16(1):714-745. PubMed ID: 38217544
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
